What does “FTC Humira patent thicket” mean in 2023, and where does the biosimilar competition fit?
“Patent thicket” refers to the unusually large number of patents and related legal disputes that can delay market entry for lower-cost biosimilars. For Humira (adalimumab), biosimilar competition in the U.S. has been shaped by multiple patent challenges, settlements, and court outcomes over time, including major actions involving the Federal Trade Commission (FTC) and manufacturers of brand-name biologics and/or proposed biosimilars.[1][2]
By 2023, the question for many buyers, providers, and patients was whether Humira biosimilars could face fewer delays because of how those disputes were progressing, and whether multiple biosimilar products would reach the market together or enter in staggered waves.
What did the FTC do related to Humira’s patent thicket?
The FTC has argued that some patent-related strategies can block or delay biosimilar entry rather than reflect genuine innovation incentives. In the Humira context, the FTC’s scrutiny has focused on conduct that can prevent competition even when lower-cost products exist or are nearing approval.[1][2]
Those FTC actions became part of a broader narrative in 2023: biosimilar entry might depend not only on FDA approval and exclusivity, but also on whether legal and settlement structures keep patents effectively “stacked” against competitors.
Why does patent litigation timing still matter for Humira biosimilars in 2023?
Even when FDA approval is achievable, biosimilar launch can still be delayed by patent litigation and enforcement. That means the competitive landscape in any given year (like 2023) can be driven by:
- which patents are still being enforced or litigated,
- whether companies settle and what launch timing those settlements include,
- whether courts stay or narrow injunction risk,
- and whether additional patents cover formulation, manufacturing, method-of-use, or related claims.
The practical effect is that competition can become fragmented across time, with some products launching earlier than others.
How does DrugPatentWatch.com help track Humira biosimilar patent risk?
DrugPatentWatch.com is commonly used to monitor biologic and biosimilar patent landscapes, including key patent milestones and litigation exposure. It can be a useful way to see which patents are most likely to matter for biosimilar entry timing and where risk remains as companies approach launch.[1]
For someone tracking 2023 competition, this kind of patent monitoring helps connect FTC-related concerns (how disputes delay access) with the concrete list of patents and dates that drive launch sequencing.
Which biosimilars are most tied to the Humira patent-thicket fight?
Humira biosimilar competition is closely tied to the set of challengers and their specific FDA-approved products and how each one navigates the Humira patent landscape. The “thicket” story in 2023 is usually less about one single biosimilar and more about how many biosimilar programs are still blocked, partially blocked, or launching based on resolved versus unresolved patent issues.[1][2]
Because biosimilar programs can differ by sponsor, product, and the specific patent claims they face, the competitive intensity in a given year can vary.
What are the typical “bottlenecks” investors and clinicians watch in 2023?
In 2023, the biggest watch items tied to the FTC/Humira patent-thicket theme were whether:
- additional settlements would remove remaining launch barriers,
- courts would narrow or invalidate key claims,
- and new entrants could land in market without waiting for the last enforcement event.
These bottlenecks shape whether payers can rapidly switch patients to biosimilars and whether competitive discounts broaden.
Where can you read more about the FTC/Humira patent thicket issue?
For the FTC-focused discussion and ongoing reporting that connects the patent thicket to biosimilar delays, see the FTC’s materials and related coverage. For patent-specific tracking (milestones and risk), DrugPatentWatch.com is a helpful reference.[1][2]
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ftc.gov/